There is very little evidence of benefit for pharmacological interventions in the management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according to a Cochrane meta-analysis.
The analysis included 99 unique studies of 16 treatments in 9119 men with CP/CPPS.
The authors found low‐ to very low‐quality evidence …

A phase 3 study has shown that finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, can reduce the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.
According to manufacturer Bayer, finerenone added to standard therapy reduced the combined risk of time to …

Active surveillance of patients with low-risk (Grade 1) prostate cancer can keep patients treatment-free for many years, according to a new US study published in The Journal of Urology. 
In a retrospective evaluation of a large active surveillance cohort, the authors reported a treatment-free survival at …

The NHS Blood and Transplant Service is calling for men who have recovered from COVID-19 infection to donate plasma for use in clinical trials.
Men are needed because their plasma is particularly rich in antibodies. Of donations received so far from men, 43% had high enough …

Prostate cancer has become the UK’s most commonly diagnosed cancer for the first time, according to Prostate Cancer UK (PCUK).
Prostate cancer has overtaken breast, lung and bowel cancer to become the most commonly diagnosed overall with 57 192 diagnoses according to latest annual figures. Prostate cancer diagnoses have more than doubled over the …

Men’s health is generally absent from policies and programmes at all levels, according to a new report from the Global Action on Men’s Health.
From the Margins to the Mainstream takes an in-depth look at the role of policy in men’s health. As well as identifying …

There have been media reports that bald men are at higher risk of COVID-19 and should be treated with caution, according to a ‘Fact Check’ by Channel Four News.
The research that led to the claims was conducted in Madrid and published pre-print in the Journal …

Enzalutamide has previously been shown to significantly improve metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA levels while taking androgen-deprivation therapy (ADT). Final results from the PROSPER trial show that overall survival is also increased. 
The final analysis shows that the …

A novel oral gonadotropin-releasing hormone (GnRH) antagonist has shown superior testosterone suppression compared to a standard injectable luteinizing hormone–releasing hormone (LHRH).
In the phase 3 trial 622 patients with advanced prostate cancer received the new agent relugolix (120 mg orally once daily) and 308 received leuprolide …

Androgen deprivation therapy (ADT) should be added to external beam radiotherapy (EBRT) in patients with localised prostate cancer and improves overall survival (OS) more than adding a brachytherapy boost (BT), according to a meta-analysis published in the Journal of Clinical Oncology.
Six trials compared EBRT with …